Clin2
NCT07778641Possibly a fitNot yet recruiting

Genetic study of auditory neuropathy spectrum disorder (ANSD) caused by the OTOF gene

Auditory Neuropathy Spectrum DisorderAuditory Neuropathy

Part of Brain & nervous system, Ear, nose & throat clinical trials.

This study looks at the genes that cause a specific type of hearing loss called auditory neuropathy spectrum disorder (ANSD), where sound reaches the ear but the brain has trouble processing it. By studying DNA from people with this condition, researchers hope to better understand the genetic causes and improve diagnosis and treatment.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
30 people
Ages
Any age
Study type
Observational

Who can take part

  • You have a diagnosis of auditory neuropathy spectrum disorder (a hearing issue where sound reaches the ear but the brain has trouble understanding it) that is not linked to a larger medical syndrome.
  • Your hearing test shows that you can hear sounds but have trouble understanding speech, and the brain's response to sound is abnormal.
  • You may have some inner ear responses (otoacoustic emissions) that are present, which is often seen in this condition.
  • You are willing to give permission (informed consent) to be in the study.
  • You do not have hearing loss caused by factors like being born early, lack of oxygen, or severe jaundice.
  • You do not have hearing loss that is part of a syndrome (like Usher or Waardenburg), and you do not have a cochlear implant in both ears.
  • You do not have structural problems in the inner ear or the hearing nerve.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05402813Recruiting
Study of hearing loss in children with GJB2 or OTOF gene changes

This study follows children with hearing loss caused by changes in specific genes (GJB2 or OTOF). It helps researchers understand how hearing develops over time and how children may do with or without cochlear implants.

Paris
NCT05572073Recruiting
Study of otoferlin hearing loss over time

This study follows people with hearing loss caused by changes (mutations) in the otoferlin gene to better understand how hearing and hearing-related test results change over time. It may help researchers prepare for future treatments by building a clear picture of the natural course of the condition.

Iowa City, Iowa
NCT06722170Recruiting
Gene therapy study for hearing loss caused by OTOF gene mutation

This trial tests a gene therapy called EH002 for people with severe or profound hearing loss due to changes in the OTOF gene. The treatment aims to help the ear hear better by replacing the faulty gene.

Zhengzhou, Henan
NCT05946057Recruiting
Registry study for people with otoferlin hearing loss

This study builds a patient registry and tracks the natural history of hearing loss in people whose genetic test shows changes in the otoferlin (OTOF) gene. It may help researchers understand how hearing symptoms progress over time and improve future treatments.

Goettigen, Lower Saxony
NCT05788536Recruiting· Phase 1/Phase 2
Gene therapy study for OTOF-related hearing loss

This trial tests a one-time gene therapy delivered into the ear to improve hearing in people with certain OTOF gene changes. It studies safety and how well the treatment can work, especially in children and infants, as doctors monitor hearing tests for up to 48 weeks.

Los Angeles, California
NCT07288580Recruiting· Phase 1/Phase 2
Gene therapy for children with inherited deafness

This trial tests an injection called EHT102 for children who have severe or profound hearing loss due to mutations in the Otoferlin gene. The goal is to see if the treatment can restore or improve hearing.

Shanghai, Shanghai Municipality

Hear when a new Auditory Neuropathy Spectrum Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.